Enzo Biochem Shares Outstanding 2010-2023 | ENZ
Enzo Biochem shares outstanding from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Enzo Biochem Annual Shares Outstanding
(Millions of Shares) |
| 2022 |
49 |
| 2021 |
48 |
| 2020 |
48 |
| 2019 |
47 |
| 2018 |
47 |
| 2017 |
46 |
| 2016 |
47 |
| 2015 |
45 |
| 2014 |
43 |
| 2013 |
40 |
| 2012 |
39 |
| 2011 |
38 |
| 2010 |
38 |
| 2009 |
38 |
Enzo Biochem Quarterly Shares Outstanding
(Millions of Shares) |
| 2023-01-31 |
49 |
| 2022-10-31 |
49 |
| 2022-07-31 |
49 |
| 2022-04-30 |
49 |
| 2022-01-31 |
48 |
| 2021-10-31 |
48 |
| 2021-07-31 |
48 |
| 2021-04-30 |
49 |
| 2021-01-31 |
48 |
| 2020-10-31 |
48 |
| 2020-07-31 |
48 |
| 2020-04-30 |
48 |
| 2020-01-31 |
48 |
| 2019-10-31 |
48 |
| 2019-07-31 |
47 |
| 2019-04-30 |
48 |
| 2019-01-31 |
47 |
| 2018-10-31 |
47 |
| 2018-07-31 |
47 |
| 2018-04-30 |
47 |
| 2018-01-31 |
47 |
| 2017-10-31 |
47 |
| 2017-07-31 |
46 |
| 2017-04-30 |
46 |
| 2017-01-31 |
46 |
| 2016-10-31 |
46 |
| 2016-07-31 |
47 |
| 2016-04-30 |
46 |
| 2016-01-31 |
47 |
| 2015-10-31 |
46 |
| 2015-07-31 |
45 |
| 2015-04-30 |
46 |
| 2015-01-31 |
45 |
| 2014-10-31 |
45 |
| 2014-07-31 |
43 |
| 2014-04-30 |
43 |
| 2014-01-31 |
42 |
| 2013-10-31 |
41 |
| 2013-07-31 |
40 |
| 2013-04-30 |
40 |
| 2013-01-31 |
39 |
| 2012-10-31 |
39 |
| 2012-07-31 |
39 |
| 2012-04-30 |
39 |
| 2012-01-31 |
39 |
| 2011-10-31 |
39 |
| 2011-07-31 |
38 |
| 2011-04-30 |
38 |
| 2011-01-31 |
38 |
| 2010-10-31 |
38 |
| 2010-07-31 |
38 |
| 2010-04-30 |
38 |
| 2010-01-31 |
38 |
| 2009-10-31 |
38 |
| 2009-07-31 |
38 |
| 2009-04-30 |
37 |
| 2009-01-31 |
37 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
